Sapanisertib - Takeda Oncology

Drug Profile

Sapanisertib - Takeda Oncology

Alternative Names: HY-13328; INK-128; MLN-0128; TAK-228

Latest Information Update: 28 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Intellikine
  • Developer Dana-Farber Cancer Institute; European Network for Translational Research in Ovarian Cancer (EUTROC); National Cancer Institute (USA); Takeda; Takeda Oncology
  • Class Antineoplastics; Benzoxazoles; Pyrazolones; Pyrimidines; Small molecules
  • Mechanism of Action MTOR protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Bladder cancer; Breast cancer; Endometrial cancer; Glioblastoma; Neuroendocrine tumours; Renal cell carcinoma; Soft tissue sarcoma; Thyroid cancer
  • Phase I/II Liver cancer; Merkel cell carcinoma; Sarcoma
  • Phase I Solid tumours
  • Discontinued Multiple myeloma; Non-small cell lung cancer; Prostate cancer; Waldenstrom's macroglobulinaemia

Most Recent Events

  • 26 Oct 2017 Pharmacokinetics, efficacy and adverse events data from a phase Ib trial in Solid tumours presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (AACR-NCI-EORTC-2017)
  • 06 Jul 2017 Takeda, in collaboration with M.D. Anderson Cancer Center plans a phase I trial for Lymphoma (Combination therapy, Second-line therapy or greater) in USA (NCT03205891)
  • 29 Jun 2017 Phase-II clinical trials in Renal cell carcinoma (Metastatic disease, Second-line therapy or greater, Monotherapy) in USA (PO) (NCT03097328)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top